SCHEMBL5367615

SCHEMBL5367615

COCCOCOc1cc(CC2CNCCN2)ccc1C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 1/20 0.43
SLC6A4 P31645 2/20 0.40
LTA4H P09960 1/20 0.38
REN P00797 5/20 0.34
PDE4A P27815 2/20 0.33
MAPK1 P28482 2/20 0.33
PDE4D Q08499 2/20 0.33
TNF P01375 1/20 0.33
LMNA P02545 1/20 0.33
MAPT P10636 1/20 0.33
PDE4B Q07343 1/20 0.33
PDE4C Q08493 1/20 0.33
PDE3B Q13370 1/20 0.33
PDE3A Q14432 1/20 0.33
KDM4E B2RXH2 1/20 0.33
MEN1 O00255 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
NFKB1 P19838 1/20 0.33
KMT2A Q03164 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL6132805 0.81 HRH3 (0.41) HRH3LTA4HPDE4AMAPK1PDE4D
SCHEMBL27268715 0.78 HRH3 (0.58) HRH3SLC6A4LTA4HRENKDM4E
SCHEMBL27166232 0.78 HRH3 (0.58) HRH3SLC6A4LTA4HRENKDM4E
SCHEMBL27166281 0.78 HRH3 (0.58) HRH3SLC6A4LTA4HRENKDM4E
Bromide SCHEMBL6132803 0.73 HRH3 (0.41) HRH3LTA4HPDE4AMAPK1PDE4D
SCHEMBL28746746 0.72 HRH3 (0.43) HRH3SLC6A4LTA4HPARP1
SCHEMBL27484596 0.72 HRH3 (0.41) HRH3LTA4HMEN1KMT2APARP1
SCHEMBL27468575 0.71 HRH3 (0.41) HRH3LTA4HPDE4AMAPK1PDE4D
SCHEMBL27508444 0.71 HTR2A (0.43) HRH3LTA4HPDE4AMAPK1PDE4D
SCHEMBL5368655 0.71 HRH3 (0.46) HRH3SLC6A4PDE4AMAPK1PDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070123532-A1 PIPERAZINE DERIVATIVES FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2007-05-31 US disclosed
US-7166598-B2 e.g 1-[3,5-bis(trifluoromethyl)benzoyl]-2-[3-[(2-methoxyethoxy)-methoxy]-4-methylbenzyl]-4-[2-[(3R)-3-methoxymethyl-morpholino]ethyl]piperazine; treating or preventing Tachykinin-mediated diseases such as asthma, emesis, an anxiety disorder, pollakiuria, urinary incontinence and irritable bowel syndrome ASTELLAS PHARMA INC. (JP) 2007-01-23 US disclosed
EP-1140924-B1 PIPERAZINE DERIVATIVES ASTELLAS PHARMA INC (JP) 2006-03-22 EP disclosed
US-20060014948-A1 e.g 1-[3,5-bis(trifluoromethyl)benzoyl]-2-[3-[(2-methoxyethoxy)-methoxy]-4-methylbenzyl]-4-[2-[(3R)-3-methoxymethyl-morpholino]ethyl]piperazine; treating or preventing Tachykinin-mediated diseases in humans or animals FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2006-01-19 US disclosed
EP-1140924-A1 PIPERAZINE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-10-10 EP disclosed
WO-2000035915-A1 PIPERAZINE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2000-06-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060014948-A1 e.g 1-[3,5-bis(trifluoromethyl)benzoyl]-2-[3-[(2-methoxyethoxy)-methoxy]-4-methylbenzyl]-4-[2-[(3R)-3-methoxymethyl-morpholino]ethyl]piperazine; treating or preventing Tachykinin-mediated diseases in humans or animals PKD2, TAC3, PKD1 HRH3 522/4885SLC6A4 551/4885LTA4H 944/4885
US-20070123532-A1 PIPERAZINE DERIVATIVES PKD2, SSTR5, IL5 HRH3 474/4885SLC6A4 221/4885LTA4H 677/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.